Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

mpl

  • Home
  •  
  • mpl



  • Most Read
  • Latest Comments
  • Medibank Backs Emyria with Landmark Depression Care Deal
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Medibank Backs Emyria with Landmark Depression Care Deal
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Medibank Backs Emyria with Landmark Depression Care Deal
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Medibank Backs Emyria with Landmark Depression Care Deal
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Medibank Backs Emyria with Landmark Depression Care Deal
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • Drug that stops growth of cancerous cells shows positive results
    Drug that stops growth of cancerous cells shows positive results
    • News

  • Megaport reports $70 million in revenue but cash burn subdues enthusiasm
    Megaport reports $70 million in revenue but cash burn subdues enthusiasm
    • News

  • PharmAust shrinks proprietary tablet for use in COVID-19 trials
    PharmAust shrinks proprietary tablet for use in COVID-19 trials
    • News

  • PharmAust is putting a leash on canine cancer, and COVID-19
    PharmAust is putting a leash on canine cancer, and COVID-19
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    • News

    Medibank Backs Emyria with Landmark Depression Care Deal

    Australia’s mental health burden is growing – and one of the toughest challenges is treatment-resistant depression (TRD). Around 4.6% of Australians experience depression in any given year, and about a third of these cases fail to respond to standard therapies. For this group, new models of care are urgently needed. Against this backdrop, Medibank Private

    Read More
    Public
  • Drug that stops growth of cancerous cells shows positive results
    • News

    Drug that stops growth of cancerous cells shows positive results

    12-year-old Louie the beagle had little time left once the vet diagnosed his lymphoma. To avoid the side effects of steroids and chemo, his parents took a chance on biotech company PharmAust’s (ASX: PAA) monepantel (MPL) drug. Within a few weeks, Louie’s lymph nodes shrunk and he enjoyed a good quality of life. Today, he

    Read More
    Public
  • Megaport reports $70 million in revenue but cash burn subdues enthusiasm
    • News

    Megaport reports $70 million in revenue but cash burn subdues enthusiasm

    Time is money. Speed is customers’ expected ROI. And data security is everything. If the recent China-US balloon war has taught us anything, it’s that your company’s intelligence is your most valuable—and hunted—asset. That’s what encouraged many organisations to initially set up their own networks to avoid exchanging sensitive information on a public one. However,

    Read More
    Public
  • PharmAust shrinks proprietary tablet for use in COVID-19 trials
    • News

    PharmAust shrinks proprietary tablet for use in COVID-19 trials

    Good things come in small packages, like PharmAust’s (ASX: PAA) newest iteration of their monepantel (MPL) tablets.  The clinical stage biotechnology company has manufactured smaller versions of their lead asset, MPL, a potent small molecule drug that has been shown to affect key pathways associated with cancer and other diseases. PharmAust have studied MPL for

    Read More
    Public
  • PharmAust is putting a leash on canine cancer, and COVID-19
    • News

    PharmAust is putting a leash on canine cancer, and COVID-19

    From high rise city apartments to the rolling hills of the countryside, you’re likely to find a dog or two snuggled up on the living room couch. Studies have proven what us dog loving people already know- that the human-canine bond is special. Owning a dog reduces stress, alleviates anxiety and even can prolong your

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.